Johnson & Johnson submits an FDA application for CAPLYTA in bipolar mania after two Phase 3 trials demonstrated significant improvements in manic symptoms.
Written By: D.Satwika, PharmD
Reviewed By: Pharmacally Editorial Team
Johnson & Johnson announced on November 19, 2026, that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA), seeking approval of CAPLYTA (lumateperone) for manic or mixed episodes associated with bipolar I disorder in adults.
The application is supported by two pivotal Phase 3 studies, Study 451 and Study 452, both of which met their primary and key secondary endpoints. CAPLYTA demonstrated significantly greater reductions in manic symptoms than placebo, with improvement observed as early as Day 3 and sustained through Week 3.
If approved, bipolar mania would become CAPLYTA’s fifth approved use in adults, extending its existing applications in schizophrenia, bipolar depression and major depressive disorder (MDD).
Bipolar I Disorder and the Need for Acute Mania Treatment
Bipolar I disorder is characterized by episodes of mania and depression. Manic episodes involve abnormally elevated or irritable mood and increased energy or activity, often accompanied by reduced need for sleep, racing thoughts, excessive talking, distractibility and risk-taking behaviour.
These episodes can escalate rapidly, affecting patients’ relationships, work, financial stability and safety. Severe episodes may require hospitalization. The World Health Organization estimates that approximately 36 million people worldwide live with bipolar disorder.
Rapid control of manic symptoms is therefore an important treatment objective, particularly during acute episodes when behavioural changes can substantially disrupt daily functioning.
Two Phase 3 Trials Support the FDA Submission
Study 451 (NCT06462586) and Study 452 (NCT06462612) were randomized, double-blind, placebo-controlled Phase 3 trials evaluating once-daily CAPLYTA 42 mg against placebo over three weeks in adults with manic episodes, with or without mixed features, associated with bipolar I disorder.
The primary endpoint in both studies was the change from baseline in the Young Mania Rating Scale (YMRS) total score at Week 3. The key secondary endpoint assessed changes in the Clinical Global Impression-Severity (CGI-S) score, which measures overall illness severity.
Both trials achieved these endpoints, providing evidence of improvement in manic symptoms as well as overall clinical severity.
Efficacy Results Demonstrate Consistent Improvement
In Study 451, CAPLYTA demonstrated a 4.8-point greater reduction in YMRS score than placebo at Week 3 (effect size -0.69; P<0.0001). The clinical response rate, defined as at least a 50% reduction in YMRS score, was 45.8% with CAPLYTA compared with 20.9% with placebo.
Study 452 also demonstrated a statistically significant benefit, with a 3.7-point greater reduction in YMRS score than placebo (effect size -0.43; P<0.0001). Response rates were 43.9% and 23.7%, respectively.
The key secondary CGI-S endpoint was also met in both studies. Study 451 demonstrated a least-squares mean difference (LSMD) of -0.5 (P<0.0001), while Study 452 showed an LSMD of -0.41 (P=0.0003).
Although the magnitude of the treatment effect differed between studies, both demonstrated statistically significant improvements across the primary and key secondary endpoints. Symptom improvement was observed as early as Day 3, following two days of treatment, and maintained through Week 3.
Safety and Tolerability Findings
Johnson & Johnson reported that CAPLYTA was generally well tolerated in both studies, with low discontinuation rates and a safety profile consistent with previous clinical experience.
In Study 452, the most common treatment-related adverse events occurring in at least 5% of CAPLYTA-treated patients and at least twice the placebo rate were dizziness, dry mouth and somnolence or sedation. The company has not provided a comprehensive account of serious adverse events and laboratory findings in its public announcement. The complete safety dataset will therefore be important for assessing the benefit-risk profile in acute mania.
Existing FDA Approvals and Regulatory Significance
CAPLYTA is currently approved in U.S. adults for schizophrenia, depressive episodes associated with bipolar I or II disorder, and as adjunctive therapy with antidepressants for MDD. For bipolar depression, it can be used alone or with lithium or valproate.
The proposed bipolar mania indication would extend its use to the acute manic phase of bipolar I disorder. However, CAPLYTA is not currently approved for manic or mixed episodes associated with bipolar I disorder.
The two positive pivotal studies provide the clinical evidence supporting the sNDA, but the FDA will independently assess the efficacy, safety and overall benefit-risk profile before reaching a decision. Johnson & Johnson has not disclosed an anticipated FDA decision date.
Clinical Outlook
The submission represents a potential expansion of lumateperone’s role in bipolar I disorder beyond depressive episodes to include acute mania. The early improvement observed in both trials is clinically relevant, although the three-week treatment period does not establish long-term response durability or prevention of future episodes.
FDA approval will depend on the agency’s assessment of the complete clinical evidence and safety data. Until then, the proposed bipolar mania use remains investigational.
References
Johnson & Johnson. Johnson & Johnson Seeks U.S. FDA Approval for CAPLYTA in Bipolar Mania, Marking Fifth Potential Indication. Nov 19, 2026
ClinicalTrials.gov. Study 451, NCT06462586. https://clinicaltrials.gov/study/NCT06462586
ClinicalTrials.gov. Study 452, NCT06462612. https://clinicaltrials.gov/study/NCT06462612
About the Writer
D. Satwika is a Pharm.D professional (Linkedin) with clinical training and an interest in medical writing, clinical research and pharmacovigilance. Her experience includes reviewing patient and medication-related data, preparing clinical case presentations and developing scientific content. She is also a published author and poster presenter, with additional training in Good Clinical Practice, scientific writing and pharmacovigilance.
She holds certifications in ICH-GCP E6(R3) from The Global Health Network, Scientific Writing in Health Research from ICMR–NIE, Pharmacovigilance Master Class from CliniWings, and Literature Search, EndNote and Publication Writing from CliniWings.
